The predicted impact and cost‐effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome

Abstract

Universal tumour testing strategies for guiding germline genetic testing of people with incident CRC for LS in Australia are likely to be cost-effective compared with no testing. Universal germline gene panel testing would not currently be cost-effective.